# A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT01283373** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 84 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** DSTP3086S
- **DRUG:** DSTP3086S

## Key facts

- **NCT ID:** NCT01283373
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2016-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01283373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01283373, "A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT01283373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*